Elevated cerebrospinal fluid and blood concentrations of oxytocin following its intranasal administration in humans

Scientific Reports

Volumn 3, Issue , 2013, Pages

  Striepens, Nadine ^a   Kendrick, Keith M ^b   Hanking, Vanessa ^a   Landgraf, Rainer ^c   Wüllner, Ullrich ^a   Maier, Wolfgang ^a,d   Hurlemann, René ^a  

^a UNIVERSITY OF BONN   (Germany)

^b UNIVERSITY OF ELECTRONIC SCIENCE AND TECHNOLOGY OF CHINA   (China)

^c MAX PLANCK INSTITUTE OF PSYCHIATRY   (Germany)

^d GERMAN CENTER FOR NEURODEGENERATIVE DISEASES DZNE   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

OXYTOCIN;

ADULT; CLINICAL TRIAL; CONTROLLED STUDY; DRUG MONITORING; HUMAN; INTRANASAL DRUG ADMINISTRATION; MALE; MIDDLE AGED; NEUROPSYCHOLOGICAL TEST; NORMAL HUMAN; RADIOIMMUNOASSAY; RANDOMIZED CONTROLLED TRIAL; TIME; YOUNG ADULT;

ADMINISTRATION, INTRANASAL; ADULT; DRUG MONITORING; HEALTHY VOLUNTEERS; HUMANS; MALE; MIDDLE AGED; NEUROPSYCHOLOGICAL TESTS; OXYTOCIN; RADIOIMMUNOASSAY; TIME FACTORS; YOUNG ADULT;

EID: 84890180888     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep03440     Document Type: Article

References (29)

1. Striepens, N., Kendrick, K. M., Maier, W. & Hurlemann, R. Prosocial effects of oxytocin and clinical evidence for its therapeutic potential. Front. Neuroendocrinol. 32, 426-450 (2011).
2. Stoop, R. Neuromodulation by oxytocin and vasopressin. Neuron 76, 142-159 (2012).
3. Zink, C. F. & Meyer-Lindenberg, A. Human neuroimaging of oxytocin and vasopressin in social cognition. Horm. Behav. 61, 400-409 (2012).
4. Macdonald, K. M. & Feifel, D. Helping oxytocin deliver: considerations in the development of oxytocin-based therapeutics for brain disorders. Front. Neurosci. 7, 35 (2013).
5. Kendrick, K. M., Keverne, E. B., Hinton,M. R. & Goode, J. A. Cerebrospinal fluid and plasma concentrations of oxytocin and vasopressin during parturition and vaginocervical stimulation in the sheep. Brain Res. Bull. 26, 803-807 (1991).
6. Mens, W. B., Laczi, F., Tonnaer, J. A., de Kloet, E. R. & van Wimersma Greidanus, T. B. Vasopressin and oxytocin content in cerebrospinal fluid and in various brain areas after administration of histamine and pentylenetetrazol. Pharmacol. Biochem. Behav. 19, 587-591 (1983). (Pubitemid 14232522)
7. Neumann, I. D., Maloumby, R., Beiderbeck, D. I., Lukas, M. & Landgraf, R. Increased brain and plasma oxytocin after nasal and peripheral administration in rats and mice. Psychoneuroendocrinology 38, 1985-1993 (2013).
8. Born, J. et al. Sniffing neuropeptides: a transnasal approach to the human brain. Nat. Neurosci. 5, 514-516 (2002). (Pubitemid 34568991)
9. Chen, X. Q., Fawcett, J. R., Rahman, Y. E., Ala, T. A.&Frey, I.W.Delivery of nerve growth factor to the brain via the olfactory pathway. J. Alzheimers Dis. 1, 35-44 (1998).
10. Ross, T. M. et al. Intranasal administration of interferon beta bypasses the bloodbrain barrier to target the central nervous system and cervical lymph nodes: a noninvasive treatment strategy for multiple sclerosis. J. Neuroimmunol. 151, 66-77 (2004). (Pubitemid 38624401)
11. Landgraf, R. Plasma oxytocin concentrations in man after different routes of administration of synthetic oxytocin. Exp. Clin. Endocrinol. 85, 245-248 (1985). (Pubitemid 15099279)
12. Burri, A., Heinrichs, M., Schedlowski, M. & Kruger, T. H. The acute effects of intranasal oxytocin administration on endocrine and sexual function in males. Psychoneuroendocrinology 33, 591-600 (2008).
13. Gossen, A. et al. Oxytocin plasma concentrations after single intranasal oxytocin administration - a study in healthy men. Neuropeptides 46, 211-215 (2012).
14. van Ijzendoorn, M. H., Bhandari, R., van der Veen, R., Grewen, K. M. & Bakermans-Kranenburg, M. J. Elevated salivary levels of oxytocin persist more than 7 h after intranasal administration. Front. Neurosci. 6, 174 (2012).
15. Horvat-Gordon, M., Granger, D. A., Schwartz, E. B., Nelson, V. J. & Kivlighan, K. T. Oxytocin is not a valid biomarker when measured in saliva by immunoassay. Physiol. Behav. 16, 445-448 (2005). (Pubitemid 40342599)
16. Chang, S. W., Barter, J. W., Ebitz, R. B., Watson, K. K. & Platt, M. L. Inhaled oxytocin amplifies both vicarious reinforcement and self reinforcement in rhesus macaques (Macaca mulatta). Proc. Natl. Acad. Sci. U S A 109, 959-964 (2012).
17. Thorne, R. G., Pronk, G. J., Padmanabhan, V. & Frey, W. H. 2nd. Delivery of insulin-like growth factor-I to the rat brain and spinal cord along olfactory and trigeminal pathways following intranasal administration. Neuroscience 127, 481-496 (2004). (Pubitemid 38950662)
18. Dhuria, S. V.,Hanson, L. R. & Frey, W. H. 2nd. Novel vasoconstrictor formulation to enhance intranasal targeting of neuropeptide therapeutics to the central nervous system. J. Pharmacol. Exp. Ther. 328, 312-320 (2009).
19. Amico, J. A., Tenicela, R., Johnston, J. & Robinson, A. G. A time-dependent peak of oxytocin exists in cerebrospinal fluid but not in plasma of humans. J. Clin. Endocrinol. Metab. 57, 947-951 (1983). (Pubitemid 14204292)
20. Kagerbauer, S. M. et al. Plasma oxytocin and vasopressin do not predict neuropeptide concentrations in the human cerebrospinal fluid. J. Neuroendocrinol. 25, 668-673 (2013).
21. Ekstedt, J. CSF hydrodynamic studies in man. Normal hydrodynamic variables related to CSF pressure and flow. J. Neurol. Neurosurg. Psychiatry 41, 345-353 (1978). (Pubitemid 8293317)
22. Linninger, A. A. et al. Cerebrospinal fluid flow in the normal and hydrocephalic human brain. IEEE Trans. Biomed. Eng. 54, 291-302 (2007). (Pubitemid 46188172)
23. First, M. B., Gibbon, M., Spitzer, R. L., Williams, J. B. W. & Benjamin, L. S. Structured Clinical Interview for DSM-IV Axis II Personality Disorders, SCID-II. (American Psychiatric Press, 1997).
24. First, M. B., Spitzer, R. L., Gibbon, M. & Williams, J. B. W. Structured Clinical Interview for DSM-IV-TR Axis IDisorders, Research Version,Non-patient Edition, SCID-I/NP. (Biometrics Research Dept., New York State Psychiatric Institute, 2002).
25. Horn, W. L-P-S Leistungsprufsystem. (Hogrefe, 1983).
26. Lehrl, S. Mehrfachwahl-Wortschatz-Intelligenztest, MWT-B. (Spitta Verlag, 2005).
27. Reitan, R. M. Validity of the Trail Making test as an indicator of organic brain damage. Percept. Mot. Skills 8, 271-276 (1958).
28. Beck, A. T.,Ward, C. H., Mendelson, M. & Mock, J. An inventory for measuring depression. Arch. Gen. Psychiatry 6, 561-571 (1961).
29. Guastella, A. J. et al. Recommendations for the standardisation of oxytocin nasal administration and guidelines for its reporting in human research. Psychoneuroendocrinology 38, 612-625 (2013).